細胞名稱：人卵巢癌細胞OVCA433
產品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運輸方式：常溫保溫運輸；干冰運輸
安全等級：1
用途限制：僅供科研2類
培養(yǎng)體系：DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡介：人卵巢癌細胞OVCA433取自女性供體，貼壁培養(yǎng)。
注釋：Part of:Cancer Cell Line Encyclopedia(CCLE)project.
Part of:COSMIC cell lines project.
Doubling time:102.24 hours(https://www.synapse.org/#!Synapse:syn2347014).
Microsatellite instability:Stable(MSS)(Sanger).
Omics:Deep exome analysis.
Omics:Deep proteome analysis.
Omics:Deep RNAseq analysis.
Omics:DNA methylation analysis.
Omics:Exosome proteome analysis.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
基因突變：/
HLA信息：/
STR信息
Amelogenin X
CSF1PO 12,13
D2S1338 19,20
D3S1358 15,16
D5S818 11,12
D7S820 11,12
D8S1179 14,15
D13S317 7,12
D16S539 12
D18S51 14
D19S433 13
D21S11 30
FGA 24
Penta D 13,14
Penta E 7,12
TH01 9
TPOX 9,11
vWA 16,18
參考文獻
PubMed=24434149;DOI=10.1016/j.bbrc.2013.12.070
Sinha A.,Ignatchenko V.,Ignatchenko A.,Mejia-Guerrero S.,Kislinger T.
In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem.Biophys.Res.Commun.445:694-701(2014)
PubMed=25485619;DOI=10.1038/nbt.3080
Klijn C.,Durinck S.,Stawiski E.W.,Haverty P.M.,Jiang Z.,Liu H.,Degenhardt J.,Mayba O.,Gnad F.,Liu J.,Pau G.,Reeder J.,Cao Y.,Mukhyala K.,Selvaraj S.K.,Yu M.,Zynda G.J.,Brauer M.J.,Wu T.D.,Gentleman R.C.,Manning G.,Yauch R.L.,Bourgon R.,Stokoe D.,Modrusan Z.,Neve R.M.,de Sauvage F.J.,Settleman J.,Seshagiri S.,Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat.Biotechnol.33:306-312(2015)
PubMed=27397505;DOI=10.1016/j.cell.2016.06.017
Iorio F.,Knijnenburg T.A.,Vis D.J.,Bignell G.R.,Menden M.P.,Schubert M.,Aben N.,Goncalves E.,Barthorpe S.,Lightfoot H.,Cokelaer T.,Greninger P.,van Dyk E.,Chang H.,de Silva H.,Heyn H.,Deng X.,Egan R.K.,Liu Q.,Mironenko T.,Mitropoulos X.,Richardson L.,Wang J.,Zhang T.,Moran S.,Sayols S.,Soleimani M.,Tamborero D.,Lopez-Bigas N.,Ross-Macdonald P.,Esteller M.,Gray N.S.,Haber D.A.,Stratton M.R.,Benes C.H.,Wessels L.F.A.,Saez-Rodriguez J.,McDermott U.,Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=27561551;DOI=10.1038/ncomms12645
Coscia F.,Watters K.M.,Curtis M.,Eckert M.A.,Chiang C.Y.,Tyanova S.,Montag A.,Lastra R.R.,Lengyel E.,Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat.Commun.7:12645-12645(2016)
PubMed=28273451;DOI=10.1016/j.celrep.2017.02.028
Medrano M.,Communal L.,Brown K.R.,Iwanicki M.,Normand J.,Paterson J.,Sircoulomb F.,Krzyzanowski P.,Novak M.,Doodnauth S.A.,Saiz F.S.,Cullis J.,Al-Awar R.,Neel B.G.,McPherson J.,Drapkin R.,Ailles L.,Mes-Massons A.-M.,Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep.18:2343-2358(2017)
PubMed=30894373;DOI=10.1158/0008-5472.CAN-18-2747
Dutil J.,Chen Z.,Monteiro A.N.,Teer J.K.,Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res.79:1263-1273(2019)
